Thiogenesis Therapeutics (TSXV:TTI) 1-Year Share Buyback Ratio : -17.10% (As of Sep. 2024 )

View and export this data going back to 2022. Start your Free Trial

What is Thiogenesis Therapeutics 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Thiogenesis Therapeutics's current 1-Year Share Buyback Ratio was -17.10%.

TSXV:TTI's 1-Year Share Buyback Ratio is ranked worse than
54.08% of 1202 companies
in the Biotechnology industry
Industry Median: -13.8 vs TSXV:TTI: -17.10

Competitive Comparison of Thiogenesis Therapeutics's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Thiogenesis Therapeutics's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thiogenesis Therapeutics's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thiogenesis Therapeutics's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Thiogenesis Therapeutics's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Thiogenesis Therapeutics 1-Year Share Buyback Ratio Calculation

Thiogenesis Therapeutics's 1-Year Share Buyback Ratio for the quarter that ended in Sep. 2024 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2023 )	-	Shares Outstanding (EOP) (Sep. 2024 ))	/	Shares Outstanding (EOP) (Sep. 2023 )
	=	(38.862	-	45.510)	/	38.862
	=	-17.1%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thiogenesis Therapeutics (TSXV:TTI) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Thiogenesis Therapeutics 1-Year Share Buyback Ratio Related Terms

Thiogenesis Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Thiogenesis Therapeutics Corp (TSXV:TTI) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

TTIPF:USA Q8M:Germany

Address

4 King Street West, Suite 401, Toronto, ON, CAN, M5H 1B6

Website

https://www.thiogenesis.com

Thiogenesis Therapeutics Corp is a clinical-stage biotech company. The Company is developing thiol-active therapeutic compounds, that are prodrugs, used to treat unmet pediatric medical needs. TTI-0102, the Company's compound, was developed to address the obstacles facing previous thiol-based drugs, their short half-live, and side effects and it's initial applications are for mitochondrial disease, Rett syndrome, and pediatric NASH.

Executives

Vincent P. Stanton

10% Security Holder